Aerosol interleukin-2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis

Pediatric Blood and Cancer

Volumn 61, Issue 8, 2014, Pages 1362-1368

  Guma, Sergei R ^a   Lee, Dean A ^a   Ling, Yu ^a   Gordon, Nancy ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aerosol interleukin 2; Cytokines; Immunotherapy; Lung metastasis; Natural killer cells; Osteosarcoma

Indexed keywords

BROXURIDINE; RECOMBINANT INTERLEUKIN 2; TECIN; UNCLASSIFIED DRUG;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; EUTHANASIA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER; LUNG METASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SPLEEN;

AEROSOL INTERLEUKIN-2; CYTOKINES; IMMUNOTHERAPY; LUNG METASTASIS; NATURAL KILLER CELLS; OSTEOSARCOMA;

ADMINISTRATION, INHALATION; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; FEMALE; HETEROGRAFTS; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM METASTASIS; OSTEOSARCOMA;

EID: 84901979493     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25019     Document Type: Article

References (37)

1. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21:2011-2018.
2. Kim HJ, Chalmers PN, Morris CD. Pediatric osteogenic sarcoma. Curr Opin Pediatr 2010; 22:61-66.
3. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res 2009; 152:3-13.
4. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival--A report from the Children's Oncology Group. J Clin Oncol 2008; 26:633-638.
5. Johal S, Ralston S, Knight C. Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: A cost-effectiveness analysis. Value Health 2013; 16:1123-1132.
6. Anderson PM, Meyers, P., Kleinerman, E, et al. Mifamurtide in metastatic and recurrent osteosarcoma: A patient access study with pharmacokinetic, pharmacodynamic, and safety assessments. Pediatr Blood Cancer 2014; 61:238-244.
7. Kager L, Potschger U, Bielack S. Review of mifamurtide in the treatment of patients with osteosarcoma. Ther Clin Risk Manag 2010; 6:279-286.
8. Huang G, Ling Yu, Cooper, JNL. et al. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res 2012; 72:271-281.
9. Guma SR, Lee DA, Yu L, et al. Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis. Pediatr Blood Cancer 2014; 61:618-626.
10. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-2100.
11. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: Challenging its predictive value. Blood 2007; 110:433-440.
12. Hsu KC, Gooley T, Malkki M, et al. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant 2006; 12:828-836.
13. Symons HJ, Leffell MS, Rossiter ND, et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010; 16:533-542.
14. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102:814-819.
15. Clausen J, Wolf D, Petzer AL, et al. Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol 2007; 148:520-528.
16. van der Meer A, Schaap NP, Schattenberg AV, et al. KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients. Mol Immunol 2008; 45:3631-3638.
17. Verheyden S, Schots R, Duquet W, et al. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005; 19:1446-1451.
18. Brand JM, Meller B, Von Hof K, et al. Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Dev 2004; 13:307-314.
19. Waldmann TA. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6:595-601.
20. van Helden MJ, de Graaf N, Boog CJ, et al. The bone marrow functions as the central site of proliferation for long-lived NK cells. J Immunol 2012; 189:2333-2337.
21. van Helden MJ, Zaiss DM, Sijts AJ. CCR2 defines a distinct population of NK cells and mediates their migration during influenza virus infection in mice. PLoS ONE 2012; 7:e52027.
22. Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors 2010; 36:274-288.
23. Denman CJ, Senyukov VV, Somanchi SS, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 2012; 7:e30264.
24. Warren HS, Rana PM. An economical adaptation of the RosetteSep procedure for NK cell enrichment from whole blood, and its use with liquid nitrogen stored peripheral blood mononuclear cells. J Immunol Methods 2003; 280:135-138.
25. Ando K, Mori K, Corradini N, et al. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother 2011; 12:285-292.
26. Kleinerman ES, Gano JB, Johnston DA, et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995; 18:93-99.
27. Morrison BE, Park SJ, Mooney JM, et al. Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J Clin Invest 2003; 112:1862-1870.
28. Prlic M, Gibbs J, Jameson SC. Characteristics of NK cell migration early after vaccinia infection. J Immunol 2005; 175:2152-2157.
29. Cosman D, Müllberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14:123-133.
30. Price JE. Spontaneous and experimental metastasis models: Nude mice. Methods Mol Biol 2014; 1070:223-233.
31. Biron CA, Young HA, Kasaian MT. Interleukin 2-induced proliferation of murine natural killer cells in vivo. J Exp Med 1990; 171:173-188.
32. Bhatnagar N, Hong HS, Krishnaswamy JK, et al. Cytokine-activated NK cells inhibit PMN apoptosis and preserve their functional capacity. Blood 2010; 116:1308-1316.
33. Tsuchiya T, Nakao N, Yamamoto S, et al. NK1.1(+) cells regulate neutrophil migration in mice with Acinetobacter baumannii pneumonia. Microbiol Immunol 2012; 56:107-116.
34. Malhotra A, Shanker A. NK cells: Immune cross-talk and therapeutic implications. Immunotherapy 2011; 3:1143-1166.
35. Bellora F, Castriconi R, Dondero A, et al. The interaction of human natural killer cells with either unpolarized or polarized macrophages results in different functional outcomes. Proc Natl Acad Sci USA 2010; 107:21659-21664.
36. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008; 9:503-510.
37. Zhang T, Sentman CL. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol 2013; 190:2455-2463.